ArticleIndian journal of surgical oncology2025
To Assess the Predictive and Prognostic Role of PD-L1 and CD8 Following Neoadjuvant Chemotherapy in Breast Cancer.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy (NACT), introduced in 1970 for inoperable tumors, has become the standard treatment approach in locally advanced breast cancer (LABC). Pathological complete response (pCR) following NACT is an important indicator for disease-free survival. An increased number of CD8-positive tumor-infiltrating lymphocytes (TILs) in the tumor center is thought to indicate an effective antitumor-immune response. Aberrant expression of programmed death ligand-1 (PD-L1) allows tumor cells to escape the host immune system. Change in PD-L1 expression may serve as an indirect indicator to assess the response to NACT. The residual cancer burden (RCB) category defined by routine histopathological evaluation represents the extent of residual disease and may predict disease-free survival. In this study, we assessed the expression of PD-L1 and CD8 in pre- and post-NACT specimens and their role in predicting pathological response to NACT. This study was conducted for a period of 3 years at Uttar Pradesh University of Medical Sciences, Saifai. PD-L1 and CD8 expression was compared on pre- and post-NACT tissue specimens. Pathological response to NACT was assessed by the RCB system. A total of 62 cases were evaluated. The mean age of patients was 47.58 ± 11.16 years. Six (9.7%) patients achieved pCR (RCB-0). PD-L1 and CD8 expression was found to be positively associated with pathological response (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.